1. |
NICE rules zanamivir OK for at-risk adults |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
Treatment options for cerebral venous thrombosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
Vaccination rates improve after pharmacist-initiated intervention |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
GDNF gene therapy: potent benefits in Parkinson's disease? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
'Endostatin' - first clinical results promising in cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 7-8
Ed Susman,
Preview
|
|
摘要:
Three phase I trials of the antiangiogenesis agent 'Endostatin' confirm that the genetically-engineered protein has low toxicity, is well tolerated and has pharmacokinetics similar to that reported in preclinical trials. Furthermore, 'Endostatin' has biological activity against solid tumours, researchers reported at the 11th NCI-EORTC-AACR*Symposium on New Drugs in Cancer Therapy [Amsterdam, The Netherlands; November 2000].'We look for certain things in phase I trials',explained Dr James Thomas from the University of Wisconsin Medical School, Madison, US,'and we saw all of these occur with endostatin'.The 3 trials, which are the first clinical trial results of the drug to be reported, involved 61 patients who had a variety of solid tumours. The patients were not receiving any medication aside from 'Endostatin', so researchers said that it seemed fair to attribute the promising results seen in the trials to the drug.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
IT methylprednisolone beneficial in postherpetic neuralgia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Valsartan beneficial in heart failure - results from Val-HeFT |
|
Inpharma Weekly,
Volume &NA;,
Issue 1266,
2000,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
Valsartan appears to significantly reduce the combined risk of mortality and morbidity in patients with heart failure who are also receiving standard therapy, according to the results of Val-HeFT*, a landmark clinical study presented at the 73rd Scientific Sessions of the American Heart Association [New Orleans, US; November 2000]. Novartis, who sponsored the trial, says it will now file an application for valsartan ['Diovan'] in heart failure, based on the positive results of the trial.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|